Patrick Delavault

A phase 3 trial of local chemotherapy with biodegradable carmustine(BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma

Manfred Westphal, Dana Hilt, Enoch Bortey et al. · Neuro-Oncology · 2003 · 1.3K citations · Full text

Medicine, Oncology, Surgery +17

A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma

Manfred Westphal, Dana Hilt, Enoch Bortey et al. · Neuro-Oncology · 2003 · 101 citations · Full text

Medicine, Oncology, Surgery +16

The Novel Sequence-Specific DNA Cross-Linking Agent SJG-136 (NSC 694501) Has Potent and Selective <b> <i>In vitro</i> </b> Cytotoxicity in Human B-Cell Chronic Lymphocytic Leukemia Cells with Evidence of a p53-Independent Mechanism of Cell Kill

Chris Pepper, Rachel M. Hambly, Chris Fegan et al. · Cancer Research · 2004 · 28 citations · Full text

Medicine, Oncology, Pharmacology +10

Population pharmacokinetic/pharmacodynamic modeling of drug-induced adverse effects of a novel homocamptothecin analog, elomotecan (BN80927), in a Phase I dose finding study in patients with advanced solid tumors

Iñaki F. Trocóniz, J. M. Cendros, Elena Soto et al. · Cancer Chemotherapy and Pharmacology · 2012 · 25 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

Fludarabine-mediated suppression of the excision repair enzyme ERCC1 contributes to the cytotoxic synergy with the DNA minor groove crosslinking agent SJG-136 (NSC 694501) in chronic lymphocytic leukaemia cells

Chris Pepper, Helen L. Lowe, Chris Fegan et al. · British Journal of Cancer · 2007 · 19 citations · Full text

Life Sciences, Molecular Biology, Oncology +15